Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Liu

Showing results (381-390 of 420) with videos related to

Pageof 42
Sort By:
Journal of the American Academy of Child and Adolescent Psychiatry|August 30, 2011
Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disordersPaula D Riggs, Theresa Winhusen, Robert D Davies, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 25, 2022
Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert studyJules Gregory, Lambros Tselikas, Caroline Allimant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2019
Progression Risk Stratification of Asymptomatic Waldenström MacroglobulinemiaMark Bustoros, Romanos Sklavenitis-Pistofidis, Prashant Kapoor, et al.
Science (New York, N.Y.)|April 20, 2023
Oncogenic <i>CDK13</i> mutations impede nuclear RNA surveillanceMegan L Insco, Brian J Abraham, Sara J Dubbury, et al.
The Lancet. Oncology|May 17, 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialEugene D Kwon, Charles G Drake, Howard I Scher, et al.
The Journal of Clinical Investigation|May 20, 2020
Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapyLina Such, Fang Zhao, Derek Liu, et al.
NPJ Precision Oncology|November 1, 2022
Prediction of early-stage melanoma recurrence using clinical and histopathologic featuresGuihong Wan, Nga Nguyen, Feng Liu, et al.
Science Translational Medicine|January 13, 2017
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressionsMarc Damelin, Alexander Bankovich, Jeffrey Bernstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL studyPhilip J Johnson, Shukui Qin, Joong-Won Park, et al.
Journal of Substance Abuse Treatment|March 30, 2020
Documented opioid use disorder and its treatment in primary care patients across six U.S. health systemsDenise M Boudreau, Gwen Lapham, Eric A Johnson, et al.
Pageof 42

Showing results (381-390 of 420) with videos related to

Sort By:
Pageof 42
Journal of the American Academy of Child and Adolescent Psychiatry|August 30, 2011
Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disordersPaula D Riggs, Theresa Winhusen, Robert D Davies, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 25, 2022
Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert studyJules Gregory, Lambros Tselikas, Caroline Allimant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2019
Progression Risk Stratification of Asymptomatic Waldenström MacroglobulinemiaMark Bustoros, Romanos Sklavenitis-Pistofidis, Prashant Kapoor, et al.
Science (New York, N.Y.)|April 20, 2023
Oncogenic <i>CDK13</i> mutations impede nuclear RNA surveillanceMegan L Insco, Brian J Abraham, Sara J Dubbury, et al.
The Lancet. Oncology|May 17, 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialEugene D Kwon, Charles G Drake, Howard I Scher, et al.
The Journal of Clinical Investigation|May 20, 2020
Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapyLina Such, Fang Zhao, Derek Liu, et al.
NPJ Precision Oncology|November 1, 2022
Prediction of early-stage melanoma recurrence using clinical and histopathologic featuresGuihong Wan, Nga Nguyen, Feng Liu, et al.
Science Translational Medicine|January 13, 2017
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressionsMarc Damelin, Alexander Bankovich, Jeffrey Bernstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL studyPhilip J Johnson, Shukui Qin, Joong-Won Park, et al.
Journal of Substance Abuse Treatment|March 30, 2020
Documented opioid use disorder and its treatment in primary care patients across six U.S. health systemsDenise M Boudreau, Gwen Lapham, Eric A Johnson, et al.
Pageof 42